TNF and inflammatory bowel disease: Subsequently, a reduction in pro-inflammatory macrophage polarization ascribed to anti-TNF treatment (e.g., infliximab) and a declination in monocyte accumulation on account of anti-α4β7 integrin therapy (e.g., vedolizumab) lead to clinical remission in IBD [18, 19].